EVMN
Evommune, Inc.
1W: -3.8%
1M: -16.9%
3M: +35.5%
YTD: +33.9%
$23.13
+2.11 (+10.04%)
After Hours: $21.96 (-1.16, -5.04%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$297.7M
52W Range13.885-33.2
Volume448,792
Avg Volume639,333
Beta0.00
Dividend—
Analyst Ratings
Company Info
CEOLuis C. Pena
Employees45
SectorHealthcare
IndustryBiotechnology
IPO Date2025-11-06
Websiteevommune.com
1841 Page Mill Road
Palo Alto, CA 94304
US
Palo Alto, CA 94304
US
(925) 247-4487
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Latest News
HC Wainwright Has Bearish Estimate for Evommune Q1 Earnings
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Evommune, Inc. (NYSE:EVMN) Receives Average Rating of “Moderate Buy” from Analysts
1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade
Evommune, Inc. GAAP EPS of -$11.22, revenue of $13M
Recent Insider Trades
No insider trades found